Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis

Journal of Rheumatology

Volumn 29, Issue 10, 2002, Pages 2074-2076

  Jansen, Annemarie L M A ^a   Van der Horst Bruinsma, Irene E ^a   Van Schaardenburg, Dirkjan ^a   Van de Stadt, Rob J ^a   De Koning, Margret H M T ^a   Dijkmans, Ben A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies; Cyclic citrullinated peptide; Diagnosis; Early rheumatoid arthritis; Undifferentiated polyarthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; PEPTIDE; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CITRULLINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 0036791894     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Smolen JS. Autoantibodies in rheumatoid arthritis. In: Venrooij WJ, Maini RN, editors. Manual of biological markers of disease. Dordrecht: Kluwer Academic Publishers; 1996.
2. Jonsson T, Steinsson K, Jonsson H, Geirsson AJ, Thorsteinsson J, Valdimarsson H. Combined elevation of IgM and IgA rheumatoid factors has very high diagnostic specificity for rheumatoid arthritis. Rheumatol Int 1998;18:119-22.
3. Swedler W, Wallman J, Froelich CJ, Teodorescu M. Routine measurement of IgM, IgG and IgA rheumatoid factors: High sensitivity, specificity and predictive value for rheumatoid arthritis. J Rheumatol 1997;24:1037-44.
4. van Jaarsveld CHM, ter Borg EJ, Jacobs JWG, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999;17:689-97.
5. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA. Citrulline is an essential constituent of antigenic determinants recognised by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
6. Kroot EJA, de Jong BAW, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
7. Schellekens GA, Visser H, de Jong BAW, et al. The diagnostic properties of rheumatoid arthritis antibodies recognising cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. van der Horst-Bruinsma IE, Speyer I, Visser H, Breedveld FC, Hazes JM. Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998;37:1084-8.
10. Jansen LMA, van Schaardenhurg D, van der Horst-Bruinsma IE, Bezemer PD, Dijkmans BAC. Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis 2000;59:223-6.